Outcome of entire patient cohort (n = 133)
| . | Day 100 . | 1 year . | 3 years . | 5 years . | P . |
|---|---|---|---|---|---|
| Overall survival | 82.7 (76.3-89.1) | 61.7 (53.4-69.9) | 53.0 (44.5-61.6) | 46.1 (36.9-55.2) | |
| Disease stage at HSCT | |||||
| Early | 88.9 (77.0-100.7) | 63.0 (44.7-81.2) | 63.0 (44.7-81.2) | 57.7 (38.3-77.1) | .30* |
| Advanced | 81.1 (73.7-88.6) | 61.3 (52.0-70.6) | 50.4 (40.8-60.1) | 43.0 (32.8-53.2) | |
| Patient age | |||||
| Younger than 55 y | 84.0 (73.8-94.2) | 66.0 (52.9-79.1) | 60.0 (46.4-73.6) | 54.8 (40.6-69.0) | .29* |
| 55 y or older | 81.9 (73.6-90.2) | 59.0 (48.5-69.6) | 48.9 (38.1-59.8) | 40.8 (29.1-52.5) | |
| Donor | |||||
| Related | 82.4 (73.3-91.4) | 64.7 (53.3-76.1) | 58.7 (47.0-70.4) | 48.9 (36.3-61.5) | .37* |
| Unrelated | 83.1 (74.0-92.2) | 58.5 (46.5-70.4) | 47.0 (34.6-59.3) | 44.6 (32.1-57.1) | |
| Donor sex | |||||
| Female | 86.0 (76.9-95.0) | 70.2 (58.3-82.1) | 64.6 (52.2-77.1) | 56.8 (43.0-70.6) | .07* |
| Male | 80.3 (71.3-89.2) | 55.3 (44.1-66.4) | 44.4 (33.1-55.6) | 38.4 (26.8-50.0) | |
| Event free survival | 79.7 (72.9-86.5) | 56.4 (48.0-64.8) | 46.4 (37.9-54.9) | 41.9 (33.1-50.7) | |
| Disease stage at HSCT | |||||
| Early | 88.9 (77.0-100.7) | 59.3 (40.7-77.8) | 55.6 (36.8-74.3) | 50.5 (31.0-70.0) | .35* |
| Advanced | 77.4 (69.4-85.3) | 55.7 (46.2-65.1) | 44.0 (34.5-53.5) | 39.6 (29.8-49.4) | |
| Patient age | |||||
| Younger than 55 y | 78.0 (66.5-89.5) | 64.0 (50.7-77.3) | 56.0 (42.2-69.8) | 48.2 (33.8-62.6) | .20* |
| 55 y or older | 80.7 (72.2-89.2) | 51.8 (41.1-62.6) | 40.6 (30.0-51.3) | 38.4 (27.4-49.3) | |
| Donor | |||||
| Related | 82.4 (73.3-91.4) | 64.7 (53.3-76.1) | 54.3 (42.4-66.2) | 46.5 (34.1-59.0) | .14* |
| Unrelated | 76.9 (66.7-87.2) | 47.7 (35.5-59.8) | 38.1 (26.2-50.0) | 38.1 (26.2-50.0) | |
| Donor sex | |||||
| Female | 86.0 (76.9-95.0) | 68.4 (56.4-80.5) | 59.2 (46.3-72.1) | 51.7 (37.9-65.5) | .04** |
| Male | 75.0 (65.3-84.7) | 47.4 (36.1-58.6) | 36.8 (25.9-47.6) | 34.6 (23.6-45.6) | |
| Relapse | 1.5 (0.4-6.0) | 12.0 (7.6-19.0) | 16.7 (11.4-24.5) | 20.1 (14.0-28.7) | |
| Disease stage at HSCT | |||||
| Early | 0.0 | 3.7 (0.5-25.3) | 3.7 (0.5-25.3) | 3.7 (0.5-25.3) | .07* |
| Advanced | 1.9 (0.5-7.4) | 14.2 (8.9-22.6) | 20.1 (13.7-29.4) | 24.3 (17.0-34.7) | |
| Donor | |||||
| Related | 2.9 (0.8-11.5) | 10.3 (5.1-20.8) | 11.8 (6.1%-22.6) | 15.7 (8.8-27.9) | .13* |
| Unrelated | 0.0 | 13.8 (7.6-25.4) | 22.0 (13.8%-35.0) | 24.4 (15.6-38.1) | |
| NRM | 15.8 (10.7-23.4) | 26.3 (19.8-35.0) | 30.3 (23.3-39.2) | 33.9 (26.4-43.5) |
| . | Day 100 . | 1 year . | 3 years . | 5 years . | P . |
|---|---|---|---|---|---|
| Overall survival | 82.7 (76.3-89.1) | 61.7 (53.4-69.9) | 53.0 (44.5-61.6) | 46.1 (36.9-55.2) | |
| Disease stage at HSCT | |||||
| Early | 88.9 (77.0-100.7) | 63.0 (44.7-81.2) | 63.0 (44.7-81.2) | 57.7 (38.3-77.1) | .30* |
| Advanced | 81.1 (73.7-88.6) | 61.3 (52.0-70.6) | 50.4 (40.8-60.1) | 43.0 (32.8-53.2) | |
| Patient age | |||||
| Younger than 55 y | 84.0 (73.8-94.2) | 66.0 (52.9-79.1) | 60.0 (46.4-73.6) | 54.8 (40.6-69.0) | .29* |
| 55 y or older | 81.9 (73.6-90.2) | 59.0 (48.5-69.6) | 48.9 (38.1-59.8) | 40.8 (29.1-52.5) | |
| Donor | |||||
| Related | 82.4 (73.3-91.4) | 64.7 (53.3-76.1) | 58.7 (47.0-70.4) | 48.9 (36.3-61.5) | .37* |
| Unrelated | 83.1 (74.0-92.2) | 58.5 (46.5-70.4) | 47.0 (34.6-59.3) | 44.6 (32.1-57.1) | |
| Donor sex | |||||
| Female | 86.0 (76.9-95.0) | 70.2 (58.3-82.1) | 64.6 (52.2-77.1) | 56.8 (43.0-70.6) | .07* |
| Male | 80.3 (71.3-89.2) | 55.3 (44.1-66.4) | 44.4 (33.1-55.6) | 38.4 (26.8-50.0) | |
| Event free survival | 79.7 (72.9-86.5) | 56.4 (48.0-64.8) | 46.4 (37.9-54.9) | 41.9 (33.1-50.7) | |
| Disease stage at HSCT | |||||
| Early | 88.9 (77.0-100.7) | 59.3 (40.7-77.8) | 55.6 (36.8-74.3) | 50.5 (31.0-70.0) | .35* |
| Advanced | 77.4 (69.4-85.3) | 55.7 (46.2-65.1) | 44.0 (34.5-53.5) | 39.6 (29.8-49.4) | |
| Patient age | |||||
| Younger than 55 y | 78.0 (66.5-89.5) | 64.0 (50.7-77.3) | 56.0 (42.2-69.8) | 48.2 (33.8-62.6) | .20* |
| 55 y or older | 80.7 (72.2-89.2) | 51.8 (41.1-62.6) | 40.6 (30.0-51.3) | 38.4 (27.4-49.3) | |
| Donor | |||||
| Related | 82.4 (73.3-91.4) | 64.7 (53.3-76.1) | 54.3 (42.4-66.2) | 46.5 (34.1-59.0) | .14* |
| Unrelated | 76.9 (66.7-87.2) | 47.7 (35.5-59.8) | 38.1 (26.2-50.0) | 38.1 (26.2-50.0) | |
| Donor sex | |||||
| Female | 86.0 (76.9-95.0) | 68.4 (56.4-80.5) | 59.2 (46.3-72.1) | 51.7 (37.9-65.5) | .04** |
| Male | 75.0 (65.3-84.7) | 47.4 (36.1-58.6) | 36.8 (25.9-47.6) | 34.6 (23.6-45.6) | |
| Relapse | 1.5 (0.4-6.0) | 12.0 (7.6-19.0) | 16.7 (11.4-24.5) | 20.1 (14.0-28.7) | |
| Disease stage at HSCT | |||||
| Early | 0.0 | 3.7 (0.5-25.3) | 3.7 (0.5-25.3) | 3.7 (0.5-25.3) | .07* |
| Advanced | 1.9 (0.5-7.4) | 14.2 (8.9-22.6) | 20.1 (13.7-29.4) | 24.3 (17.0-34.7) | |
| Donor | |||||
| Related | 2.9 (0.8-11.5) | 10.3 (5.1-20.8) | 11.8 (6.1%-22.6) | 15.7 (8.8-27.9) | .13* |
| Unrelated | 0.0 | 13.8 (7.6-25.4) | 22.0 (13.8%-35.0) | 24.4 (15.6-38.1) | |
| NRM | 15.8 (10.7-23.4) | 26.3 (19.8-35.0) | 30.3 (23.3-39.2) | 33.9 (26.4-43.5) |